Skip to content

Psychedelic-assisted therapy: all studies

Page 65 of 294: studies 641 to 650 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline.

American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Mahdi Fadel et al.

Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is renewed scientific interest in mescaline because of the potential psychiatric benefits of psychedelic-assisted therapy. Mescaline primarily exerts its psychoactive effects through serotonin-2A (5-HT 2A ) receptor agonism. There is a lack of controlled clinical...

Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA).

American Journal of Therapeutics Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al.

After becoming notorious for its use as a party drug in the 1980s, 3,4-methylenedioxy-methampetamine (MDMA), also known by its street names "molly" and "ecstasy," has emerged as a powerful treatment for post-traumatic stress disorder (PTSD). There are extensive data about the risk profile of MDMA. However, the literature is significantly biased. Animal models demonstrating neurotoxic or adverse...

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ketamine.

American Journal of Therapeutics Viviana D. Evans, Alejandro Arenas, Kenneth Shinozuka et al. 10 citations

Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid-onset, well-understood cardiovascular effects and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the Food and Drug Administration in 2019 for both treatment-resistant depression and major depressive disorder with suicidal...

DOI: 10.1097/MJT.0000000000001721 (opens in new tab) Full text (opens in new tab) Mental health Depression treatment Ketamine therapy Psychiatric medicine +1

Psychedelic Therapy: A Primer for Primary Care Clinicians-The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics.

American Journal of Therapeutics Owen S. Muir, Kenneth Shinozuka, Bryce D. Beutler et al. 5 citations

The reviews in this special edition have presented a primer on the state of the literature for 7 different psychedelic compounds and their plausible roles in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader health care landscape for indicated conditions. Historically,...

DOI: 10.1097/MJT.0000000000001720 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Psychiatric medicine Drug research +1

Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.

American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 12 citations

Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including those that are treatment-resistent. The latter half of the 20th century marked a revolution in the treatment of mental illnesses, exemplified by the introduction of selective serotonin reuptake inhibitors and other...

DOI: 10.1097/mjt.0000000000001727 (opens in new tab) Full text (opens in new tab) Mental health treatment Clinical research Psychedelics Alternative medicine +1

Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD).

American Journal of Therapeutics Bryce D. Beutler, Kenneth Shinozuka, Burton J. Tabaac et al. 11 citations

Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use disorder. However, LSD was banned in 1970 in part because of concerns that it could bring about or exacerbate mental illness. Its therapeutic potential remains incompletely understood. While uncontrolled recreational use of LSD can, in rare...

DOI: 10.1097/mjt.0000000000001726 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Anxiety disorders Clinical research +1

Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.

American Journal of Therapeutics Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al. 12 citations

N,N-dimethyltryptamine (DMT) is a naturally occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT. Although previous...

DOI: 10.1097/mjt.0000000000001725 (opens in new tab) Full text (opens in new tab) Traditional medicine Psychedelics Mental health Alternative medicine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.

American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 14 citations

The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is...

DOI: 10.1097/mjt.0000000000001724 (opens in new tab) Full text (opens in new tab) Mental health treatment Clinical trials Psychedelics Psilocybin therapy +1

Epistemic Discipline in Psychedelic-Assisted Therapy: Memory, Therapy Dynamics, Attachment Patterns, and Sexual Abuse

Neuroethics December 1, 2026 Guy Simon, James W. Hopper, Aaron D. Cherniak et al.

Abstract: Psychedelic-assisted therapy (PAT) is increasingly used for trauma-related disorders, raising ethical questions beyond client safety. We argue that PAT clients have epistemic needs and clinicians have corresponding obligations that call for epistemic humility and discipline, which are essential for regulating foreseeable epistemic risks and for PAT's ethical structure. Drawing on...

Embodied Transformation: Psychedelic Therapy Through the Lens of Merleau-Ponty’s Phenomenology

Integrative Psychological and Behavioral Science December 1, 2026 Zinet Ritschel, Brady Wagoner

Abstract This paper develops a phenomenological account of the therapeutic significance of psychedelic-induced mystical experience, drawing on the philosophy of Maurice Merleau-Ponty. The central argument holds that the enduring therapeutic benefits of psychedelics emerge through a radical transformation in the structure of lived experience. Two prominent objections to the therapeutic value of...